Policy & Regulation
Humacyte submits Israel MAA for Symvess arterial trauma repair
...
Sentynl Therapeutics and PRG S&T enter licensing agreement for potential HGPS treatment
17 March 2026 - US biopharmaceutical company Sentynl Therapeutics Inc, a wholly-owned subsidiary of Zydus Lifesciences Limited, announced on Monday that it has signed an agreement with PRG S&T, a ...
ONL Therapeutics reports start of European Phase 2 trial of xelafaslatide for GA associated with dry AMD
17 March 2026 - ONL Therapeutics Inc, a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, announced on Monday that the fir...
NeuroSense Therapeutics reports Phase 2b trial results of PrimeC in ALS
17 March 2026 - Late-stage clinical biotechnology company NeuroSense Therapeutics Ltd (NASDAQ:NRSN) announced on Monday that results from the Phase 2b clinical trial (PARADIGM) of PrimeC in people liv...
Avacta opens Phase 1 trial for AVA6103 cancer therapy in US
16 March 2026 - Biopharmaceutical company Avacta Group plc (AIM:AVCT) reported on Monday that it has opened a Phase 1 clinical trial for FAP-Exd (AVA6103), its second pipeline programme and the first ...
Imfinzi approved in EU for perioperative treatment of early gastric and gastroesophageal cancers
...